The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer.
 
Charlie Gourley
Honoraria - AstraZeneca; Cor2Ed; Medscape; Tesaro
Consulting or Advisory Role - AstraZeneca; Cor2Ed; Foundation One Inc (Inst); Nucana (Inst); Roche (Inst); Tesaro (Inst)
Research Funding - Aprea AB (Inst); AstraZeneca (Inst); Novartis (Inst); Nucana (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - One patent issued and four pending for a gene expression signature to predict cancer sensitivity to anti-angiogenic therapy. (Inst)
 
Heather J. Dalton
No Relationships to Disclose
 
Susana N. Banerjee
Consulting or Advisory Role - AstraZeneca (Inst); AstraZeneca/MedImmune; Clovis Oncology (Inst); GamaMabs Pharma; Roche (Inst); Tesaro; Tesaro (Inst)
Research Funding - AstraZeneca (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; Tesaro
 
Joseph Buscema
Stock and Other Ownership Interests - McKesson
 
Michelle Lockley
No Relationships to Disclose
 
Jonathan Krell
Consulting or Advisory Role - AstraZeneca; Tesaro
Travel, Accommodations, Expenses - AstraZeneca
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Janssen; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Consulting or Advisory Role - Abbvie; Advaxis; Amgen; AstraZeneca; Bayer; Biodesix; Cerulean Pharma; Clovis Oncology; GlaxoSmithKline; Gradalis; Immunogen; Incyte; Insys Therapeutics; Mateon Therapeutics; Merck; Myriad Pharmaceuticals; Nucana; Oxigene; Perthera; Pfizer; Precision Oncology; Roche/Genentech; Tesaro; Verastem; Vermillion
Speakers' Bureau - AstraZeneca; Clovis Oncology; Janssen; Roche/Genentech; Tesaro
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)